SORAFENIB-EVEROLIMUS

NCT01804374 📎

Regimen

Experimental
Sorafenib + everolimus combination
Control
None (vs pre-specified PFS6 benchmark of 50%)

Population

Relapsed/refractory osteosarcoma progressing on standard chemo, age >=18

Key finding

Adding mTOR inhibition to sorafenib did not clear the pre-defined futility bar, though numerically similar to sorafenib alone. Combination toxicity was substantial. Another example of 'add a drug, lose on tolerability'.

Source: PMID 25498219

Timeline

    Guideline citations

    • NCCN BONE (p.31)